Novartis, BeiGene lay out frontline PhIII data for PD-1 drug as second-line PDUFA date looms

As the FDA prepares to decide on Novartis and BeiGene’s PD-1 drug tislelizumab in the second-line setting, the pair is already preparing for its potential use as patients’ first treatment option.